Haemonetics Corporation (NYSE:HAE) shares climbed 3% in premarket trading Thursday after the medical technology company posted strong fiscal second-quarter results that topped Wall Street expectations and prompted an upgrade to its full-year guidance.
For the quarter ended September 27, Haemonetics reported adjusted earnings of $1.27 per share, beating the analyst consensus of $1.11. Revenue came in at $327 million, above expectations of $311.46 million, though down 5.3% year over year due to portfolio transitions and currency impacts.
Excluding those effects, the company achieved organic ex-CSL revenue growth of 9.4%, underscoring solid momentum across its business segments.
“Our second quarter results demonstrate disciplined execution and increasingly profitable growth across our business—growing cash flow, earnings and operating income while absorbing the impact from last year’s portfolio transitions,” said Chris Simon, Haemonetics’ CEO.
The company’s adjusted operating margin expanded to 26.7%, an improvement of 250 basis points compared with the previous year, supported by pricing gains, market share growth in Plasma, and favorable product mix. Free cash flow surged to $88.7 million, up nearly 140% year over year.
Following the robust quarter, Haemonetics raised its fiscal 2026 outlook, now projecting adjusted EPS between $4.80 and $5.00, compared with the prior range of $4.70–$5.00. The company also increased its free cash flow target to $170–$210 million, up from $160–$200 million previously.
During the quarter, Haemonetics repurchased 1.43 million shares for $75 million under its ongoing $500 million share buyback program, further signaling confidence in its long-term growth trajectory.